Vaccine (RSV) – 222090 (extension to 212494)

A phase 3b, randomized, open label, multi-country, multi-center, extension and crossover vaccination study to evaluate the immunogenicity and safety of different revaccination schedules and persistence of a single dose of the RSVPreF3 OA vaccine in adults aged 60 years and above who participated in the RSV OA=ADJ-006 study.

Register Today!

Trial Information

Start DateMay, 2024
End Date~ 2026
Number of Visits12 visits, 11 Phone calls every 24 weeks

For additional information
on this trial contact:

Phone(705) 566-0005